Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Inclusion Criteria:

* Histologically confirmed marginal zone B-cell lymphomas
* Failure to achieve a clinical benefit (≥SD) with the initial treatment, or recurrent disease
* Performance status (ECOG) ≤2
* Age ≥ 20
* At least one or more bi-dimensionally measurable lesion(s) defined as; ≥2 cm by conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or measurable lesion by physical examination
* Adequate kidney functions defined as; Cr \< 2.0 mg% or Ccr \> 60 ml/min
* Adequate liver functions defined as; Transaminases \< 3 X upper normal values; Bilirubin \< 2 mg%
* Adequate bone marrow functions defined as; ANC \> 1500/㎕, platelet \> 75000/㎕
* Ann Arbor stage III or IV
* Ann Arbor stage I or II, which is not adequate for RT or surgical approach (e.g. multiple lung lesions, multiple colon involvement, remote abdominal LN with stomach involvement)
* Written informed consent approved by Institutional review board or Ethic committee

Exclusion Criteria:

* Any other malignancies within the past 5 years except skin basal cell ca or CIS of cervix
* Serious co-morbid diseases
* Pregnancy or breast feeding
* Previous history of drug allergy to one of the drugs in the study regimen
* During this study duration, patients who take other clinical trial medication, chemotherapy, hormonal therapy, or immunotherapy